192
Participants
Start Date
March 26, 2021
Primary Completion Date
January 31, 2025
Study Completion Date
December 31, 2025
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.
Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide
Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
Placebo matching empagliflozin and placebo pen injector matching semaglutide
Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
Wiener Gesundheitsverbund, Klinik Landstraße, Vienna
Medizinische Universität Graz, Graz
Franziskus-Krankenhaus Berlin, Berlin
Leber- und Studienzentrum Checkpoint, Berlin
University Clinics Berlin Charité, Berlin
University Clinics Berlin Charité, Berlin
Städtisches Klinikum Brandenburg GmbH, Brandenburg
Herz- und Diabeteszentrum NRW, Bad Oeynhausen
Städtisches Klinikum Braunschweig gGmbH, Braunschweig
German Diabetes Center, Düsseldorf
Universitätsklinikum Düsseldorf, Düsseldorf
University Clinics Bochum, Bochum
University Clinics Essen, Essen
University Clinics Johannes-Gutenberg Mainz, Mainz
University Clinics Frankfurt, Frankfurt
University Clinics Heidelberg, Heidelberg
University Clinics Tübingen, Tübingen
University Clinics Freiburg, Freiburg im Breisgau
TUM, München
Universitätsklinikum Ulm, Ulm
University Clinics Würzburg, Würzburg
Medizinische Universität Innsbruck, Innsbruck
Medizinische Universität Wien, Vienna
Wiener Gesundheitsverbund, Klinik Hietzing, Vienna
University Clinics Carl Gustav Carus Dresden, Dresden
Eugastro GmbH, Leipzig
Lead Sponsor
Boehringer Ingelheim
INDUSTRY
German Center for Diabetes Research
OTHER
Federal Ministry of Health, Germany
OTHER_GOV
Ministry of Innovation, Science and Research in North Rhine-Westphalia
UNKNOWN
Novo Nordisk A/S
INDUSTRY
German Diabetes Center
OTHER